Tesamorelin: its one approved use, and the research beyond it
Tesamorelin has one approved use, in adults with HIV. Research outside that use is limited, and no other use is established.
TL;DR
- Tesamorelin is FDA-approved only as the brand drug Egrifta, to reduce excess abdominal fat in adults with HIV and lipodystrophy.
- Its mechanism — stimulating the pituitary to release growth hormone — is the same biological pathway as CJC-1295 and sermorelin.
- Other uses, including visceral fat in adults without HIV, are not approved and not established. Compounded tesamorelin is not the same as Egrifta.
What it is
Tesamorelin is a GHRH analog (in plain English: a synthetic version of growth hormone-releasing hormone — the signal your hypothalamus sends to the pituitary gland to release growth hormone). It works by mimicking the body's natural GHRH signal, prompting the pituitary to release its own GH in a physiologically pulsatile (rhythmic, burst-based) pattern — rather than administering GH directly.
Unlike most research peptides, tesamorelin has gone through full FDA clinical trials. It received approval in 2010, as the brand drug Egrifta, for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy (abnormal fat redistribution).
How it works
The mechanism is the same as other GHRH-class secretagogues: tesamorelin binds to GHRH receptors on pituitary cells (the key enters the lock), triggering GH release. The GH then signals the liver to produce IGF-1, which mediates many of the downstream effects on metabolism and body composition — including effects on visceral adipose tissue (the fat stored around internal organs, associated with metabolic risk).
In HIV-positive patients with lipodystrophy, phase 3 trials showed tesamorelin reduced visceral adipose tissue over 26 weeks compared to placebo (JCEM, 2010).
Research outside HIV
In HIV patients, the visceral fat accumulation tesamorelin targets is driven partly by antiretroviral therapy and partly by GH axis suppression — both of which increase visceral fat. Some researchers have asked whether the same mechanism might apply in adults without HIV.
That question is not answered. Evidence in adults without HIV is limited, and no use outside the approved one is established.
Who asks about it
People in longevity or performance medicine contexts who've heard about tesamorelin and want to understand how it differs from CJC-1295 or sermorelin — and why it has an FDA approval when similar peptides don't.
What is approved and what is not
Tesamorelin's approval covers one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. Other uses are not approved and not established. Compounded tesamorelin is not the same as Egrifta.
The Halftime POV
Tesamorelin has stronger trial evidence than most GHRH-class peptides, because the approval process required it. That evidence is for adults with HIV and lipodystrophy. It does not show that tesamorelin is safe or effective for anyone outside that group.
Related reading:
- What IGF-1 measures and why it matters
- CJC-1295: mechanism and research
- DEXA body composition testing explained
FAQ
Q: What is tesamorelin FDA-approved for? A: Only the brand drug Egrifta is FDA-approved, to reduce excess abdominal fat in adults with HIV and lipodystrophy — a fat redistribution condition that can occur as a side effect of antiretroviral therapy. This is its only approved use. Other uses are not approved and not established, and compounded tesamorelin is not FDA-approved.
Q: Has tesamorelin been shown to reduce visceral fat in people without HIV? A: No. Published research in adults without HIV is limited, and that use is not approved and not established. The trials that led to approval studied adults with HIV and lipodystrophy.
Q: How does tesamorelin compare to CJC-1295? A: Both are GHRH-class peptides that stimulate the pituitary to release GH. Tesamorelin is a more direct GHRH analog; CJC-1295 includes a DAC (Drug Affinity Complex) modification that extends its half-life. Tesamorelin has FDA-trial data; CJC-1295 does not.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Sources
- FDA — Egrifta (tesamorelin) label, 2010
- Falutz J et al., "Metabolic effects of a growth hormone-releasing factor in patients with HIV," NEJM, 2007
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is tesamorelin FDA-approved for?
Only the brand drug Egrifta is FDA-approved, to reduce excess abdominal fat in adults with HIV and lipodystrophy — a fat redistribution condition that can occur as a side effect of antiretroviral therapy. This is its only approved use. Other uses are not approved and not established, and compounded tesamorelin is not FDA-approved.
Has tesamorelin been shown to reduce visceral fat in people without HIV?
No. Published research in adults without HIV is limited, and that use is not approved and not established. The trials that led to approval studied adults with HIV and lipodystrophy.
How does tesamorelin compare to CJC-1295?
Both are GHRH-class peptides that stimulate the pituitary to release GH. Tesamorelin is a more direct GHRH analog; CJC-1295 includes a DAC (Drug Affinity Complex) modification that extends its half-life. Tesamorelin has FDA-trial data; CJC-1295 does not.
